{
    "code": "06023359",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=06023359",
    "time": "2020-02-25 20:30:26",
    "許可證字號": "衛署醫器輸字第023359號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "QSD8574",
    "有效日期": "111\/03\/19",
    "發證日期": "101\/03\/19",
    "許可證種類": "醫　器",
    "舊證字號": "",
    "醫療器材級數": "第二等級",
    "通關簽審文件編號": "DHA00602335906",
    "中文品名": "亞培臨床生化直接膽紅素檢驗試劑組",
    "英文品名": "Abbott Clinical Chemistry Direct Bilirubin",
    "效能": "定量檢測人類血清或血漿中之直接膽紅素濃度，須搭配ARCHITECT c系統(c 4000, c 8000, c16000)及AEROSET系統使用。",
    "醫器規格": "8G63-21,以下空白\r\n\r\n規格變更 (干擾宣稱及刪除適用機型)\r\n仿單標籤變更為：詳如中文仿單核定本。(原101年3月30日仿單標籤核定本正本收回作廢)。以下空白。",
    "劑型": "",
    "包裝": "",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "醫器主類別一": "A臨床化學及臨床毒理學",
    "醫器次類別一": "A1110膽紅素(總量或直接的)試驗系統",
    "醫器主類別二": "",
    "醫器次類別二": "",
    "醫器主類別三": "",
    "醫器次類別三": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "",
    "限制項目": "02輸　入 09委託製造",
    "申請商名稱": "0932301100  美商亞培股份有限公司台灣分公司",
    "申請商地址": "台北市中山區民生東路三段49號5樓、6樓及51號6樓",
    "主製造廠": {
        "製造廠名稱": "MCA0120000  SEKISUI DIAGNOSTICS P.E.I. INC.",
        "製造廠廠址": "70 WATTS AVENUE, CHARLOTTETOWN, PRINCE EDWARD ISLAND, C1E 2B9, CANADA",
        "製造廠公司地址": "",
        "製造廠國別": "CANADA",
        "製程": "Manufactured by"
    },
    "藥理治療分類": "",
    "ingredients": [],
    "仿單外盒": [
        {
            "title": "060233590002變更核定仿單-108-08-06.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=06023359&Seq=002&Type=9"
        },
        {
            "title": "060233590002變更核定仿單-108-08-06.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=06023359&Seq=002&Type=8"
        }
    ]
}